Tacrolimus Patent Expiration
Tacrolimus is Used for preventing organ rejection in transplant patients. It was first introduced by Astellas Pharma Us Inc
Tacrolimus Patents
Given below is the list of patents protecting Tacrolimus, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Envarsus Xr | US8644239 | Method and apparatus for allocating and processing sequences in communication system | Aug 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US8664239 | Tacrolimus for improved treatment of transplant patients | Aug 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US8685998 | Tacrolimus for improved treatment of transplant patients | Aug 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US10166190 | Stabilized tacrolimus composition | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US10864199 | Tacrolimus for improved treatment of transplant patients | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US11110081 | Tacrolimus for improved treatment of transplant patients | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US11123331 | Tacrolimus for improved treatment of transplant patients | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US11419823 | Stabilized tacrolimus composition | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US12083103 | Tacrolimus for improved treatment of transplant patients | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US12403095 | Stabilized Tacrolimus Composition | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US9549918 | Stabilized tacrolimus composition | May 30, 2028 | Veloxis Pharms Inc |
| Envarsus Xr | US10548880 | Solid dispersions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US11077096 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US7994214 | Solid dispersions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8486993 | Solid dispersions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8586084 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8591946 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8617599 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8623410 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8623411 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8889185 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US8889186 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US9161907 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US9757362 | Modified release compositions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Envarsus Xr | US9763920 | Solid dispersions comprising tacrolimus |
Aug 30, 2024
(Expired) | Veloxis Pharms Inc |
| Astagraf Xl | US6440458 | Sustained release preparations |
Mar 25, 2019
(Expired) | Astellas |
| Astagraf Xl | US6576259 | Sustained release formulations containing tacrolimus |
Mar 25, 2019
(Expired) | Astellas |
| Astagraf Xl | US6884433 | Sustained release formulation containing tacrolimus |
Mar 25, 2019
(Expired) | Astellas |
| Astagraf Xl | US8551522 | Sustained-release formulation |
Mar 25, 2019
(Expired) | Astellas |
| Protopic | US5665727 | Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them |
Sep 09, 2014
(Expired) | Leo Pharma As |
Tacrolimus's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tacrolimus:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
